Journal of the European Academy of Dermatology and Venereology

Cover image for Vol. 28 Issue s3

Editor-in-Chief: Prof. Dr. med. Dr. phil. Johannes Ring, München, Germany

Impact Factor: 2.694

ISI Journal Citation Reports © Ranking: 2012: 13/59 (Dermatology)

Online ISSN: 1468-3083



Author Guidelines


QUICK LINKS

Online Submission [req]
Conflicts of Interest Disclosure Form [req]
Contact the Editorial Office

1. AIMS & SCOPE

The Journal of the European Academy of Dermatology and Venereology (JEADV) is the official organ of the European Academy of Dermatology and Venereology (EADV).

JEADV publishes articles of general and practical interest in the field of dermatology and venereology including clinical and basic science topics, as well as research with practical implications. It does so through editorials, review and practice articles, original papers of general interest, short reports, case reports, letters to the editor, news items, features and Academy announcements.

2. MANUSCRIPT CATEGORIES

JEADV invites the following types of submissions:

Original articles. Original articles are the Journal’s primary mode of communication. Original articles must include a structured abstract (maximum 300 words), and should not exceed 3000 words of body text.

(Manuscripts reporting randomised controlled trials (RCTs) must follow the CONSORT statement. RCTs will not be considered by JEADV without submission of a completed CONSORT checklist.)

Review articles. The Journal is particularly keen to publish concise, high-quality review articles of recent advances in laboratory or clinical research. Review articles may be solicited by the Editor-in-Chief or may be submitted by authors for publication subject to peer review. Review articles must include an unstructured abstract (maximum 300 words), and should not exceed 3000 words of body text. Use of tables and figures is encouraged.

Short reports. Brief data papers are published as short reports. Short reports must include a structured abstract and should not exceed 1500 words of body text, 4 figures/tables and 20 references.

Letters to the Editor. Letters to the Editor (Correspondence) may be in response to issues arising from recently published articles, or short, free-standing pieces expressing an opinion. Case reports will be considered, but published as items of correspondence. Letters to the Editor do not require abstracts, should be formatted in one continuous section and should not exceed 600 words, 10 references and two figures. All letters are subject to expert review.

3. SUBMISSION OF MANUSCRIPTS

All submissions should be made online at the JEADV ScholarOne Manuscripts (formerly known as Manuscript Central) site—http://mc.manuscriptcentral.com/jeadv

New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Centre. Authors must also supply:

(i) completed Conflicts of Interest Disclosure form(s)—Each listed author must complete the form electronically. It is the responsibility of the corresponding author to upload—on behalf of all co-authors—completed forms as ‘Supplementary Material for Review’ via ScholarOne Manuscripts (formerly known as Manuscript Central) at the same time as manuscript submission. Manuscripts will not be sent for peer-review without these forms. (See section 6 for further information.)

4. CONTACTING THE EDITORIAL OFFICE

Maryse Clappier, JEADV Editorial Office, Hôpital Archet 2, Dermatology Department—BP3079, 06202 Nice Cedex 3, France
Tel: +33 4 92 03 61 19; Fax: +33 4 92 03 65 32; Email: maryse.clappier@unice.fr

5. PREPARATION OF MANUSCRIPTS

Manuscripts must be written in English.

Text should be supplied in a format compatible with Microsoft Word for Windows (PC). Charts and tables are considered textual and should also be supplied in a format compatible with Word. All figures (illustrations, diagrams, photographs) should be supplied in jpg, tiff or eps format.

All manuscripts must be typed in 12 pt font with margins of at least 2.5 cm. Submissions must comply with the word limits defined in section 2 and, where appropriate, include:

Title page. The first page of all manuscripts should contain the following information:

  1. the title of the paper
  2. a running head not exceeding 50 characters
  3. manuscript word, table and figure count
  4. names of authors as initial(s) followed by surnames
  5. names of the institutions at which the research was conducted, clearly linked to respective authors
  6. name, address, telephone and fax number, and email address of corresponding author
  7. a statement of all funding sources that supported the work
  8. any conflict of interest disclosures (see sections 3 and 6).

Abstracts. Authors submitting original articles should note that structured abstracts are required. The structured abstract should adopt the format: Background, Objective, Methods, Results, Conclusion.

Review articles require abstracts but they need not be structured. Letters to the Editor do not require abstracts. Abstracts should contain no citations to previously published work.

Text. This should in general, but not necessarily, be divided into sections with the headings: Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References, Tables, Legends and Figures.

Tables and figures. Tables and figures should not be inserted in the appropriate place in the text but should be included at the end of the manuscript, each on a separate page.

Tables and figures should be referred to in text as follows: Fig. 1, Figs 2–4; Table 1, Table 2. The place at which a table or figure is to be inserted in the printed text should be indicated clearly on the manuscript. Each table and/or figure must have a legend that explains its purpose without reference to the text. Where a figure has more than one panel, each panel should be labelled in the top left-hand corner using lower case letters in parentheses, i.e., (a), (b), etc., and a brief description of each panel given in the figure legend.

Colour illustrations are welcomed and all colour is published free of charge to the author.

Authors are themselves responsible for obtaining permission to reproduce previously published figures or tables. When an individual is identifiable in a photograph written permission must be obtained (see section 6).

If submitting artwork electronically, please read the information at:http://authorservices.wiley.com/bauthor/illustration.asp

References. References should be in Vancouver format and appear as consecutive, unbracketed superscript numbers in the text, e.g., ‘in our previous reports1,2 and those of Smith et al.3–5’ and should be listed numerically in the reference list at the end of the article.

Format references as below, using standard (Medline) abbreviations for journal titles. If more than six authors, include the first three authors followed by et al. If six or fewer authors, please include all authors' names.

  1. de Berker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran and Dawber's Diseases of the Nails and their Management (Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, eds), 3rd edn. Oxford: Blackwell Science Ltd, 2001; 172–92.
  2. Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008;22:1–6.
  3. Graham-Brown R, Burns T. Lecture Notes: Dermatology. Oxford: Wiley-Blackwell, 2006.
  4. British Lymphology Society. Consensus Document on the Management of Cellulitis in Lymphoedema. 2007. Available at: http://www.lymphoedema.org/lsn/consensus_on_cellulitis_dec_06.pdf (last accessed 28 November 2007).

Reporting standards. Manuscripts reporting randomised controlled trials (RCTs) must follow the CONSORT statement. RCTs will not be considered by JEADV without submission of a completed CONSORT checklist. Checklists should be uploaded during manuscript submission using file designation 'Supplementary files for review'.

6. DECLARATIONS

Original publication. Submission of a manuscript will be held to imply that it contains original unpublished work and is not being submitted for publication elsewhere at the same time. The author must supply a full statement to the Editor about all submissions and previous reports that might be regarded as redundant or duplicate publication of the same or very similar work.

Conflicts of interest. Authors are responsible for disclosing all financial and personal relationships between themselves and others that might be perceived by others as biasing their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. (See section 3.)

Ethics. When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution's or a national research council's guide for, or any national law on, the care and use of laboratory animals was followed. A statement describing explicitly the ethical background to the studies being reported should be included in all manuscripts in the Materials and Methods section. Ethics committee or institutional review board approval should be stated.

Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be published in written descriptions, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Identifying details should be omitted if they are not essential but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.

Authorship. All persons designated as authors should qualify for authorship and all those who qualify should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, from inception to published article. Authorship credit should be based only on (i) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; (ii) drafting the article or revising it critically for important intellectual content; (iii) final approval of the version to be published. Conditions (i), (ii) and (iii) must all be met. Acquisition of funding, the collection of data or general supervision of the research group, by themselves, do not justify authorship. All others who contributed to the work who are not authors should be named in the Acknowledgments section.

Committee on Publication Ethics (COPE). As a member of the Committee on Publication Ethics (COPE), adherence to these submission criteria is considered essential for publication in the JEADV; mandatory fields are included in the online submission process to ensure this. If, at a later stage in the submission process or even after publication, a manuscript or authors are found to have disregarded these criteria, it is the duty of the Editor to report this to COPE. COPE may recommend that action be taken, including but not exclusive to, informing the authors' professional regulatory body and/or institution of such a dereliction. The website for COPE may be accessed at: http://www.publicationethics.org.uk

7. ADDITIONAL INFORMATION ON ACCEPTANCE

Copyright. If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

Proofs. Page proofs will be sent to the corresponding author and should be returned within 3 days of receipt to the Production Editor. Significant textual alterations are unacceptable at proof stage without the written approval of the Editor, and they are likely to result in the delay of publication.

The corresponding author will receive an e-mail alert containing a link to a secure web site. A working e-mail address must therefore be provided for the corresponding author. In the absence of the corresponding author, please arrange for a colleague to access the e-mail to retrieve the proofs.

Please note that you have final responsibility for what is stated in the proofs of your manuscript. However, the proofs are checked thoroughly by the JEADV editorial team and if we do not receive corrections after several automated reminders to the email address supplied for the corresponding author then we will assume that we have your approval for publication.

Author services. Author Services enables authors to track their article—once it has been accepted—through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Early View. JEADV is covered by the Publisher’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found online at http://www.doi.org/faq.html.

Offprints. Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.

Additional offprints can be ordered on the offprint order form, which accompanies the proofs.

Disclaimer. The Publisher, the European Academy of Dermatology and Venereology (EADV) and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, the EADV and Editors or the products advertised.

SEARCH

SEARCH BY CITATION